Investigating the Utility of Remote Index of Microvascular Resistance in Patients With Chronic Total Occlusion
Launched by UNIVERSITY OF CHICAGO · Jan 8, 2020
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age ≥ 21 years
- • seen at University of Chicago Medical center with a planned PCI of a single CTO vessel
- • must have either stable angina or angina equivalent
- • must have a CTO with a clear donor vessel supplying most of the collaterals.
- Exclusion Criteria:
- • subjects with a pacemaker or implantable cardioverter defibrillator
- • contraindication to cardiac MRI, adenosine, heparin, or nitroglycerin
- • cardiac transplantation
- • Estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73m2, given the risk of contrast-induced nephropathy (CIN) and nephrogenic systemic fibrosis (NSF) associated with iodinated and gadolinium-based contrast agents, respectively, in patients with significant renal dysfunction
- • Women who may potentially be pregnant will receive a pregnancy test and be excluded if pregnant
- • Vulnerable populations such as children, college students, prisoners, non-English speakers, and those with diminished decision-making capacity
- • Inability or refusal to consent for the study.
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
John Blair, MD
Principal Investigator
University of Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials